Etavopivat Clinical Trials (2026): 13 Studies for Sickle Cell Disease & Thalassemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 Etavopivat clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Sickle Cell Disease & Thalassemia) and 1,700 total planned enrollment. 3 Phase 3 Etavopivat trials and 5 Phase 2 are listed. 4 Etavopivat clinical trials are actively recruiting at 64 U.S. sites across 25 states. Most recent activity: NCT06609226 (Dec 2030).
Where to Participate: All Etavopivat Trial Sites in the U.S. (64 sites across 25 states)
Every actively recruiting Etavopivattrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Uni of Alabama at Birmingham | Birmingham35233 | NCT06612268 | Map |
| AL | Univer South Alabama Ped/Onc | Mobile36604 | NCT06612268 | Map |
| AZ | Phoenix Children's Hsptl | Phoenix85016 | NCT06609226 | Map |
| AZ | Phoenix Children's Hsptl | Phoenix85016 | NCT06612268 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202 | NCT06612268 | Map |
| CA | Children's Hospital Los Angeles - Endocrinology | Los Angeles90027 | NCT06609226 | Map |
| CA | Children's Hospital Los Angeles - Endocrinology | Los Angeles90027 | NCT06612268 | Map |
| CA | UCLA Health | Los Angeles90095 | NCT06612268 | Map |
| CA | Valley Children's Hospital | Madera93636 | NCT06612268 | Map |
| CA | UCSF Oakland Benioff ChildHosp | Oakland94609 | NCT06609226 | Map |
| CA | University Of California Irvine | Orange92868 | NCT06609226 | Map |
| CA | Stanford University_Palo Alto | Palo Alto94304 | NCT06612268 | Map |
| CA | Harbor-UCLA Medical Center | Torrance90502 | NCT06612268 | Map |
| DE | Nemours/AI duPont Hosp-Chld | Wilmington19803 | NCT06612268 | Map |
| DC | Childrens National Medical Ctr | Washington D.C.20010 | NCT06612268 | Map |
| DC | MedStar Hlth Res Institute | Washington D.C.20010 | NCT06612268 | Map |
| FL | Foundation for Sickle Cell Disease Research | Hollywood33023 | NCT06609226 | Map |
| FL | Memorial Healthcare | Hollywood33021 | NCT06612268 | Map |
| GA | Children's Healthcare Atlanta | Atlanta30329 | NCT06609226 | Map |
| GA | Children's Healthcare Atlanta | Atlanta30329 | NCT06612268 | Map |
| GA | Center for Blood Disorders Augusta University | Augusta30912 | NCT06609226 | Map |
| IL | Childrens Hospital of Chicago | Chicago60611 | NCT06612268 | Map |
| IL | Univer Of Illinois at Chicago | Chicago60612 | NCT06609226 | Map |
| IL | Univer Of Illinois at Chicago | Chicago60612 | NCT06612268 | Map |
| LA | Children's Hosp-New Orleans | New Orleans70118 | NCT06612268 | Map |
| MA | Boston Children's Hospital | Boston02115 | NCT06612268 | Map |
| MA | Boston Medical Center | Boston02118-2393 | NCT06612268 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT06612268 | Map |
| MO | Washington University-St.Louis | St Louis63110 | NCT06609226 | Map |
| MO | Washington University-St.Louis | St Louis63110 | NCT06612268 | Map |
| NE | Children's Nebraska | Omaha68114 | NCT06612268 | Map |
| NJ | Newark Beth Israel MC | Newark07112-2027 | NCT06612268 | Map |
| NY | Interfaith Medical Center | Brooklyn11238 | NCT06612268 | Map |
| NY | NYC Health+Hospitals | Brooklyn11203 | NCT06609226 | Map |
| NY | NYC Health+Hospitals | Brooklyn11203 | NCT06612268 | Map |
| NY | Columbia University Medical Center_New York_0 | New York10032 | NCT06609226 | Map |
| NY | Weill Cornell Med Coll-NYPH | New York10065 | NCT06609226 | Map |
| NY | Cohen Children's Medical Ctr | Queens11040 | NCT06612268 | Map |
| NY | Jacobi Medical Center | The Bronx10461 | NCT06612268 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT06609226 | Map |
| NY | Montefiore Medical Ctr | The Bronx10467 | NCT06612268 | Map |
| NC | Duke Comprehen Sickle Cell | Durham27710 | NCT06612268 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06612268 | Map |
| NC | Duke University_Durham | Durham27705 | NCT06609226 | Map |
| NC | East Carolina Univ-Greenville | Greenville27834 | NCT06612268 | Map |
| NC | Atrium Health-Wake Forest Bapt | Winston-Salem27157 | NCT06609226 | Map |
| NC | Atrium Health-Wake Forest Bapt | Winston-Salem27157 | NCT06612268 | Map |
| OH | Univ Hosp Cleveland Med Ctr | Cleveland44106 | NCT06612268 | Map |
| OH | Ohio State Univ Wexner Med Ctr | Columbus43203 | NCT06612268 | Map |
| OK | Univ of OK Health Sciences Ctr | Oklahoma City73104 | NCT06612268 | Map |
| PA | Children's Hosptl Philadelphia | Philadelphia19104 | NCT06612268 | Map |
| PA | St Christopher Hosp for Child | Philadelphia19134 | NCT06612268 | Map |
| SC | Medical University Of South Carolina_Charleston | Charleston29425 | NCT06609226 | Map |
| TN | Methodist University Hospital | Memphis38104 | NCT06609226 | Map |
| TN | St. Jude Children's Res Hosp | Memphis38105 | NCT06612268 | Map |
| TN | University of Tennessee Health Science Center | Memphis38104 | NCT06612268 | Map |
| TX | Texas Children's Hospital_Houston | Houston77030 | NCT06609226 | Map |
| TX | UT Health University of Texas | Houston77030 | NCT06609226 | Map |
| TX | UT Health University of Texas | Houston77030 | NCT06612268 | Map |
| VA | Inova Health System | Fairfax22031 | NCT06612268 | Map |
| VA | Children's Hsptl Of The Kings | Norfolk23507 | NCT06612268 | Map |
| VA | Virginia Comm Univ Medical Ctr | Richmond23298 | NCT06609226 | Map |
| VA | Virginia Comm Univ Medical Ctr | Richmond23298 | NCT06612268 | Map |
| WA | Mary Bridge Children's Health | Tacoma98405 | NCT06612268 | Map |
Etavopivat clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|---|
| P1 | 5 | 5 | |||
| P2 | 2 | 2 | 1 | 5 | |
| P3 | 2 | 1 | 3 |
Recruiting Etavopivat clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06609226 | FLORALA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia | P3 | Sickle Cell Disease | 480 | Jan 2025 |
| NCT06198712 | HIBISCUS KIDSA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease | P2 | Sickle Cell Disease | 95 | Jan 2023 |
| NCT06612268 | Hibiscus 2A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | P3 | Sickle Cell Disease | 408 | Feb 2025 |
| NCT05953584 | HIBISCUS 3A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke | P2 | Sickle Cell Disease | 27 | Jun 2023 |
Etavopivat clinical trials by indication
Sickle Cell Disease (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06609226 | FLORAL | P3 | recruiting | A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia |
| NCT06198712 | HIBISCUS KIDS | P2 | recruiting | A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease |
| NCT06612268 | Hibiscus 2 | P3 | recruiting | A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease |
| NCT05953584 | HIBISCUS 3 | P2 | recruiting | A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke |
| NCT04624659 | HIBISCUS | P3 | active not recruiting | A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) |
| NCT05725902 | — | P2 | completed | Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease |
| NCT04987489 | GLADIOLUS | P2 | completed | A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease |
Healthy Volunteers (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07023029 | — | P1 | completed | A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants |
| NCT06581627 | — | P1 | completed | A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants |
Healthy Volunteers Sickle Cell Disease, Thalassemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06813924 | — | P1 | completed | A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants |
| NCT06433661 | — | P1 | completed | A Research Study of the Effect of Food on Etavopivat in Healthy Participants |
Liver Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06336018 | — | P1 | completed | A Research Study on Etavopivat in Participants With and Without Liver Disease |
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05568225 | MDS | P2 | terminated | A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) |
Etavopivat pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| FLORAL | NCT06609226 | P3 | recruiting | Sickle Cell Disease | 480 | — |
| Hibiscus 2 | NCT06612268 | P3 | recruiting | Sickle Cell Disease | 408 | — |
| HIBISCUS | NCT04624659 | P3 | active not recruiting | Sickle Cell Disease | 450 | — |
| HIBISCUS KIDS | NCT06198712 | P2 | recruiting | Sickle Cell Disease | 95 | — |
| HIBISCUS 3 | NCT05953584 | P2 | recruiting | Sickle Cell Disease | 27 | — |
| GLADIOLUS | NCT04987489 | P2 | completed | Sickle Cell Disease | 53 | — |
| MDS | NCT05568225 | P2 | terminated | Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R | 17 | — |
Terminated and withdrawn Etavopivat trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05568225terminatedA Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
All Etavopivat trials (13)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06609226 | FLORAL | A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia | P3 | recruiting | 480 | Novo Nordisk A/S | Jan 2025 |
| NCT06198712 | HIBISCUS KIDS | A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease | P2 | recruiting | 95 | Forma Therapeutics, Inc. | Jan 2023 |
| NCT06612268 | Hibiscus 2 | A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | P3 | recruiting | 408 | Novo Nordisk A/S | Feb 2025 |
| NCT05953584 | HIBISCUS 3 | A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke | P2 | recruiting | 27 | Forma Therapeutics, Inc. | Jun 2023 |
| NCT04624659 | HIBISCUS | A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) | P3 | active not recruiting | 450 | Forma Therapeutics, Inc. | Jan 2021 |
| NCT05725902 | Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease | P2 | completed | 12 | Novo Nordisk A/S | Mar 2024 | |
| NCT04987489 | GLADIOLUS | A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease | P2 | completed | 53 | Forma Therapeutics, Inc. | Mar 2022 |
| NCT07023029 | A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants | P1 | completed | 33 | Novo Nordisk A/S | Jun 2025 | |
| NCT06336018 | A Research Study on Etavopivat in Participants With and Without Liver Disease | P1 | completed | 48 | Novo Nordisk A/S | May 2024 | |
| NCT06813924 | A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants | P1 | completed | 37 | Novo Nordisk A/S | Feb 2025 | |
| NCT06581627 | A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants | P1 | completed | 24 | Novo Nordisk A/S | Aug 2024 | |
| NCT05568225 | MDS | A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS) | P2 | terminated | 17 | Forma Therapeutics, Inc. | Nov 2022 |
| NCT06433661 | A Research Study of the Effect of Food on Etavopivat in Healthy Participants | P1 | completed | 16 | Novo Nordisk A/S | May 2024 |
Etavopivat clinical trials: frequently asked questions
- How many Etavopivat clinical trials are there?
- 13 Etavopivat clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 7 are marked completed.
- Are Etavopivat clinical trials recruiting in 2026?
- Yes — 4 Etavopivat trials are actively recruiting in 2026, with 64 U.S. sites across 25 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Etavopivat being studied for?
- Etavopivat is being studied for Sickle Cell Disease, Thalassemia, Healthy Volunteers, Healthy Volunteers Sickle Cell Disease, Thalassemia, Liver Diseases and 1 more. The trials are grouped by indication on this page.
- What phase is Etavopivat in?
- Etavopivat clinical trials span 3 Phase 3, 5 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Etavopivat clinical trials?
- The lead sponsor across the most Etavopivat trials is Novo Nordisk A/S, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Etavopivatas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: